Drug Profile
EIK 1001
Alternative Names: BDB-001; EIK-1001Latest Information Update: 26 Jan 2024
Price :
$50
*
At a glance
- Originator Birdie Biopharmaceuticals
- Developer Birdie Biopharmaceuticals; Eikon Therapeutics; National Cancer Institute (France); Roche; Seven and Eight Biopharmaceuticals
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Solid tumours
Most Recent Events
- 06 Feb 2024 Phase-II clinical trials in Non small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatics disease) in USA (IV) (NCT06246110)
- 08 Jan 2024 US FDA approves IND application for EIK 1001in Cancer
- 08 Jan 2024 Eikon Therapeutics plans multiple phase II trial for cancer